News | May 10, 2021
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Enabling a new era in minimally invasive obesity treatment across Europe
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated
